ImageneBio (NASDAQ:IMA) Rating Lowered to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded ImageneBio from “hold” to “sell,” signaling a more bearish view on the biotech stock.
• The company reported a wider-than-expected loss in its latest quarterly results, posting EPS of -$0.95 versus the -$0.70 consensus estimate.
• ImageneBio shares were trading at $5.29, giving the company a market cap of about $56.34 million and leaving the stock well below its 52-week high of $18.00.

ImageneBio (NASDAQ:IMA - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

ImageneBio Price Performance

IMA stock opened at $5.29 on Friday. The stock has a market capitalization of $56.34 million, a price-to-earnings ratio of -0.66 and a beta of 0.73. The business's fifty day moving average price is $5.71 and its two-hundred day moving average price is $6.60. ImageneBio has a fifty-two week low of $3.94 and a fifty-two week high of $18.00.

ImageneBio (NASDAQ:IMA - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.25). Research analysts expect that ImageneBio will post -2.98 EPS for the current year.

Institutional Trading of ImageneBio

Large investors have recently modified their holdings of the stock. Barclays PLC grew its holdings in shares of ImageneBio by 170.8% during the 4th quarter. Barclays PLC now owns 10,797 shares of the company's stock worth $74,000 after purchasing an additional 6,810 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of ImageneBio during the 4th quarter worth $76,000. Millennium Management LLC acquired a new stake in shares of ImageneBio during the 4th quarter worth $79,000. Bridgeway Capital Management LLC acquired a new stake in shares of ImageneBio during the 3rd quarter worth $104,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of ImageneBio during the 3rd quarter worth $106,000. 75.00% of the stock is owned by institutional investors and hedge funds.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.